On June 21, 2022, Enzolytics announced it has found conserved, immutable sites (epitopes) on the Monkeypox virus. Since then ENZC has been growing slowly to $0.0680 per share. Thanks to its Comprehensive Artificial Intelligence (AI) protocol which is designed to make monoclonal antibodies.
Monkeypox is not a seriously fatal disease that is spread across central and western Africa. Biotech firms have enough time to identify the weak points of the virus. Hopefully, Enzolytics may come up with therapeutics to treat Monkeypox patients after its AI protocol will eventually let researchers find clear opportunities to tackle the spread of the virus.
The penny ENZC will be destined to gain further if it stays alert to any health challenges from any part of the globe. The recent announcement has pushed the stock to gain little. Additionally, the next positive update will pump ENZC higher.